Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica Inc (CALC) is a clinical-stage biopharmaceutical company advancing novel therapies targeting calcium release-activated calcium (CRAC) channels for severe inflammatory conditions. This page provides centralized access to official news and developments regarding their innovative pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements. Key focus areas include acute pancreatitis, kidney injury, and pediatric pancreatic toxicity treatments currently in Phase 2 trials.
The resource features verified information on Auxora™ clinical data, partnership announcements, and research publications. Content is rigorously curated to support informed analysis while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to CALC's latest press releases and objective updates on their CRAC channel inhibition therapies. Check regularly for developments in this specialized area of immunomodulation research.
CalciMedica reported a significant quarter ending March 31, 2024, marked by the completion of enrollment for the Phase 2b CARPO trial for Auxora™ in acute pancreatitis (AP), with topline data expected in 2Q 2024.
Additionally, the KOURAGE Phase 2 trial for severe acute kidney injury (AKI) will start patient enrollment in 2Q 2024, with data expected in 2025. A related abstract will be presented at Digestive Disease Week (DDW) 2024.
Financially, the company completed a $54 million private placement, with $20.4 million received upfront and $33.1 million pending from warrant exercises. With $25.7 million in cash and equivalents, operations are funded into the second half of 2025. Total operating losses were $5.8 million for Q1, offset by a $5.6 million gain from warrant liability adjustment, resulting in a $0.1 million net income.
CalciMedica Inc. announces an upcoming presentation at Digestive Disease Week 2024 where collaborators from Cedars-Sinai will present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis. The presentation will highlight the similarities between the benefits of Auxora and those seen in COVID-19 pneumonia.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
